Treats moderate acne vulgaris in females at least 15 years of age. ANDA 203870, held by Naari Pte. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 203870 (Norgestimate And Ethinyl Estradiol), held by Naari Pte, was first approved by FDA on Nov 12, 2015, with 3 approved supplements and 0 published complete response letters.
Tri Femynor is estrogen/progestin COCs, indicated for use by women to prevent pregnancy. Tri Femynor is also indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri Femynor should be used for the treatment of acne only if the patient desires an oral contraceptive birth control. 1.1 Oral Contraceptive Tri Femynor Tablets are indicated for use by females of reproductive potential to prevent pregnancy. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 12, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norgestimate And Ethinyl Estradiol0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Discontinued |
| Oct 16, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 16, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 12, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters